Shanghai Qinheli Biotechnology

Shanghai Qinheli Biotechnology is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation precision oncology treatments. The company utilizes its proprietary Tumor Microenvironment Activated (TME-activated) technology platform to engineer "smart" drugs that remain inert in systemic circulation and are selectively activated by proteases within the tumor microenvironment. This approach is designed to significantly broaden the therapeutic window of potent biologics, such as cytokines and antibodies, by minimizing off-target toxicities while enhancing anti-tumor activity. Qinheli's pipeline features several innovative candidates, including bifunctional antibodies and masked cytokines, targeting high-value pathways in solid tumors. The company's lead program, QHL1703, is a TME-activated bifunctional antibody targeting both PD-L1 and TGF-beta, currently in clinical development. Based in Shanghai, the company is supported by prominent venture capital firms and aims to provide safer, more effective immunotherapy options for cancer patients globally.